Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Hepatology. 2021 Apr 27;73(5):1855–1867. doi: 10.1002/hep.31504

Figure 2. Increased anti-CHI3L1, anti-DLL-4 and anti-SFTPD IgM autoantibodies in BA validation cohort correlates with worse outcomes.

Figure 2.

A. Serum levels of IgM autoantibodies in other liver disease controls and BA. B. Spearman correlation of IgM autoantibody level and concurrent serum bilirubin level in BA subjects. C. IgM autoantibody levels at 6–12 months post-Kasai and subsequent need for liver transplant by 2 years of life in BA. D. ROC curves of autoantibodies to predict BA versus non-BA diagnosis. E. ROC curves to predict need for liver transplant in first 2 years of life in BA.